The Top 5 Biosimilars Articles for the Week of May 4

Here are the top 5 biosimilars articles for the week of May 4, 2020.

The Center for Biosimilars® is your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of May 4, 2020.

Number 5: German investigators had difficulty understanding why a Sandoz rituximab biosimilar was preferred over a Celltrion rituximab biosimilar in a nationwide study of clinics; however, they concluded that providers were willing to use both products on an increasing basis to treat their patients.

Number 4: Biosimilar competition took a big bite out of revenues for Amgen, although the company’s own biosimilar portfolio notched impressive growth, according to Amgen’s first quarter 2020 earnings.

Number 3: Taiwan-based Mycenax, has agreed to sell its tocilizumab biosimilar, LusiNEX, to Hungary-based Gedeon Richter. The biosimilar under development is thought to have potential for treating coronavirus disease 2019 (COVID-19)—related pneumonia.

Number 2: Trying to carve back its market share for Neupogen, its filgrastim originator product, Amgen is hoping product exclusivity can be backdated.

Number 1: Pfizer is battling biosimilar competition as its brands lose exclusivity, but it is fighting fire with fire, launching multiple biosimilars of its own.

To read all of these articles and more, visit